




























































The	 transcription	 factor	p53	 is	an	 important	 tumour	 suppressor	 that	 is	 lost	or	mutated	 in	
>50%	of	human	cancers,	and	multiple	oncogenic	mechanisms	lead	to	its	degradation	by	the	
proteasome1,2.	 Consequently,	 stabilisation	 and	 (re-)activation	 of	 p53	 is	 a	 key	 aim	 of	






































































































































































































































































































































































































































































































































































































































































































GFP-USP7	 was	 subcloned	 from	 pEGFP-C-GW-USP7	 into	 pCDNA5-FRT-TO	 (Invitrogen).	 The	
coding	 sequences	 for	 F291N	 and	 Q297A	 were	 subcloned	 from	 pETNHT_USP7	 K208-E560	
(F291N)	and	pETNHT_USP7	K208-E560	(Q297A)	plasmids	into	pCDNA5-GFP-USP7.		
HCT116	Flp-In	TRex	cells	(gift	from	Stephen	Taylor,	University	of	Manchester)	were	cultured	
in	 DMEM	 with	 Glutamax	 supplemented	 with	 10	 %	 FBS,	 1	 %	 nonessential	 amino	 acids	
solution,	1	%	penicillin/streptomycin,	10	µg/mL	zeocin,	and	4	µg/mL	blasticidin	(Invitrogen).	
HCT116	 Flip-In	 Trex	 cells	 were	 transfected	 with	 Lipofectamine	 LTX,	 with	 Plus	 Reagent	
(Invitrogen),	 with	 pOG44	 and	 either	 pEF5-GFP,	 pCDNA5-GFP-USP7WT,	 pCDNA5-GFP-
USP7F291N	 or	 pCDNA5-GFP-USP7Q297A.	 Two	 days	 after	 transfection,	 Hygromycin	 B	 (50	
µg/mL,	Invitrogen)	was	added	and	cells	were	kept	under	selection	for	3	weeks.		
Stably	 transfected	 HCT116	 Flip-In	 Trex	 GFP,	 GFP-USP7WT,	 GFP-USP7F291N	 and	 GFP-
USP7Q297A	cells	were	incubated	with	0.1	µg/mL	Doxycycline	for	3	h,	and	then	treated	with	
1	µM	and	3	µM	of	FT671	or	vehicle	for	4	h	in	presence	of	doxycycline.	Cells	were	lysed	with	
RIPA	 lysis	 buffer	 supplemented	 with	 mammalian	 protease	 inhibitor	 (Sigma)	 and	































MM.1S	 were	 plated	 at	 starting	 density	 3500	 cells/well	 in	 40	 µl	 of	 RPMI-1640	 (Corning)	
supplemented	 with	 2	 mM	 L-glutamine,	 10	 %	 fetal	 bovine	 serum	 (Corning),	 1	 %	
penicillin/streptomycin,	 and	 10	 mM	 HEPES,	 pH	 7.4.	 Cells	 were	 plated	 in	 384-well	 black	
plates	 (Corning	3712)	and	 incubated	at	37	°C,	5	%	CO2	 in	humidified	atmosphere	 for	12	h	
before	DMSO-solubilised	FT671	was	added	using	an	ECHO	525	acoustic	dispenser.	The	final	
DMSO	 concentration	was	 0.5	%	 (v/v).	 After	 compound	 addition,	 cells	were	 incubated	 for	



































All	 animal	 experiments	 were	 performed	 at	 Pharmaron	 (Beijing,	 China).	 	 All	 the	 animal	
experiments	 were	 performed	 according	 to	 the	 guidelines	 approved	 by	 the	 Institutional	
Animal	 Care	 and	 Use	 Committee	 (IACUC)	 of	 Pharmaron	 (Beijing,	 China)	 following	 the	







































































































































































































Kd = 7.8 μM
kinact = 0.0003 s-1
KI = 4.2 μM 














Kd = 65 nM
IC50 = 52 nM
Pyrazolo[3,4-d]
          pyrimidin-4-one-












































































































































































































































































































































































































FT827 (50 μM) 
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FT671 + + + +








HCT116 +/- 10 μM FT671 (24h)
Extended Data Table 1
 
FT671  FT827  
USP enzymes  
  
USP1/UAF1  103  101  
USP2  101  98 
USP4  96  93 
USP5  115 92 
USP5 (1)  112  104  
USP5 (2)  110 92 
USP6  96 95 
USP7  0 14 
USP8  94 90 
USP9x  93 95 
USP11  107  103  
USP14 (3)  99 97 
USP15  100 104  
USP16  96  89 
USP19  99  108  
USP20  104 115  
USP21  100  110  
USP25  97 107  
USP28  105  108  
USP30  103 112  
USP35  103  93 
USP36  89 117  
USP45  115  125  
CYLD  100 81 
UCH enzymes    
UCHL1  101  103  
UCHL3  102 99 
UCHL5  94 101  
BAP1  88 96 
OTU enzymes    
OTU1  91 97 
OTUB2  89 95 
OTUD3  100  106  
OTUD5 pSer177  107  93 
OTUD6A  99 108  
OTUD6B  92 98 
Cezanne  95 101  
JAMM enzymes    
AMSH -LP  96  93 
AMSH -LP (+Zn)  88 87 
Josephins    
Ataxin3  92  105  
Ataxin3L  102  102  
JOSD1  96  91 
JOSD2  100 96 
 
USP10 (4) 99  N.D.
USP47 (4) 95 N.D.





α, β, γ (º)
























71.3,  70.3, 78.6
0.063 (0.856)





































Extended Data Figure 1





































USP7CD       52 (29-94) nM 
USP7C-term  69 (39-120) nM 
Catalytic Domain UBL1 UBL2 UBL3 UBL4 UBL5208 1102USP7C-term
Catalytic Domain208 560USP7CD
TRAF Catalytic Domain UBL1 UBL2 UBL3 UBL4 UBL5 11021USP7FL
0 10 20 30 40 50
RF
U
















Kd  7.8 (5.9 - 10.2) μM
kinact       0.0003 ± 0.0001 s-1 
KI   4.2 ± 1.5 μM 
kinact / KI      66 ± 25 M-1 s-1




















Kd 65 (45 - 92) nM















Extended Data Figure 2
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5 min reaction with probe 60 min reaction with probe
anti-USP7
Extended Data Figure 3
a






molecule A molecule B

















Extended Data Figure 5
USP7-FT671 vs. USP7 apo (1NB8) USP7-FT671 vs. USP4 apo (2Y6E) USP7-FT671 vs. yUBP6 apo (1VJV)
USP7-FT671 vs. USP8 apo (2GFO) USP7-FT671 vs. USP12 apo (5K16) USP7-FT671 vs. USP14 apo (2AYN)







































Ub in S1 site
HUBL5 
activation peptide in 
Switching loop pocket 
USP7 bound to C-terminal activation peptide (PDB 5JTV)
USP7 CD
WT 0.31 ± 0.029 0.39 ± 0.014
F291N 0.25 ± 0.018 1.33 ± 0.035
Q297A 0.68 ± 0.095 0.062 ± 0.0043
Y465N 0.46 ± 0.030 0.0062 ± 0.00018
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USP7CD Q297A - FT671
Kd  = N.D.






USP7CD Y465N - FT671 












USP7CD WT - ubiquitin 
Kd = 280 μM(270-300 μM)






USP7CD Q297A - ubiquitin 
Kd = 330 μM(310-350 μM)





USP7CD F291N - ubiquitin
Kd = 190 μM(170-210 μM)























-60 0 60 120 180 240 300 360
Time (s)
USP7CD Q297A - FT827 USP7CD F291N - FT827
















USP7CD Y465N - FT827
Kd = N.D.
















USP7CD Y465N - ubiquitin
Kd in μM (SEM range) 
USP7CD FT827 FT671 Ubiquitin
WT (n=9) 7.8 (5.9-10.2) 0.065 (0.045-0.092) 280 (270-300)
F291N (n=3) No binding No binding 190 (170-210)
Q297A (n=3) No binding No binding 330 (310-350)
Y465N (n=3) No binding No binding 250 (240-270)
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Vehicle 25 mg kg-1
p53
β-Actin














































































































































































200 mg kg-1 FT671
100 mg kg-1 FT671


















































































































































































































































































































































Full gel pictures for Figure 1 and E2
Figure 1d (upper panel) Figure 1d (lower panel)
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P22077FT827FT671










































































































































































































































(Santa Cruz, sc-126, mouse)
IB: p21 F5
























































































































































Full gel pictures for Figure E7
Figure E7a
IB: p53 DO1
(Santa Cruz, sc-126, mouse)
IB: p21 F5



























































































(Santa Cruz, sc-6246, mouse)
reprobed after Actin and p53
IB: p53 DO1





















































FT671( 20 h) 
IB: N-MYC
(Cell Signaling, #9405, rabbit)
IB: p53 DO1








































































































































































































































































Full gel pictures for Figure E7 (3)
10µM FT671 10µM FT671
NT 0.5h 2h 4h 8h 24h
13E5, Cell Signaling Technologies
 13E5, Cell Signalling Technologies
Santa Cruz (H-8)
Cell Signalling D63A6 XP
Figure E8a
Full gel pictures for Figure E8


















Vehicle 200 mg kg-1



















Vehicle 75 mg kg-1
Vehicle 25 mg kg-1
Vehicle 200 mg kg-1 75 mg kg-1 25 mg kg-1 24 h
Supplementary Figure 2
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